60¢sixtycents

Larimar Therapeutics, Inc.LRMR

$3.64+0.10 (+2.82%)
NASDAQHealthcare24:00 UTC

Company snapshot

Market Cap
$310M
Small-cap
+51%
2016 — today
10-Year Price
-95%
2016 — today
52-Week Range
$2.42$5.95
Current $3.64· 35%

Headquartered in Bala Cynwyd, Pennsylvania, Larimar Therapeutics, Inc. operates as a clinical-stage biotechnology firm. Its core mission involves crafting therapies for rare diseases, leveraging a distinctive cell-penetrating peptide technology platform. The company's foremost experimental therapy, CTI-1601, is presently undergoing Phase 1 clinical trials. This drug candidate is being developed to combat Friedreich's ataxia, a genetic illness that is rare, relentlessly progressive, and ultimately fatal.

Valuation in context

P/E ratio
-1.7
N/A
Not meaningful — company is unprofitable
P/B ratio
2.0
Above average
Pricier than usual over the last 10 years
FCF Yield
-42.4%
Historically low
Historically low relative to the last 10 years
Free · No credit card needed

Get alerted when LRMR is cheap

Set a free alert — we'll push you when P/E, yield, or other metrics cross a historical threshold.